ESR1 and neoplasm: Tamoxifen, which competes with estrogen for ERα and inhibits the stimulatory effect of estrogen for tumor growth, is the first‐line therapy and most widely used endocrine agent for adjuvant therapy, particularly in premenopausal women (Swaby et al, 2007).